Company Description
Mersana Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops antibody-drug conjugates (ADC) for cancer patients with unmet needs.
The company develops Emi-Le (XMT-1660), a B7-H4-targeting Dolasynthen ADC candidate, which is in Phase 1 clinical trial; and XMT-2056, an Immunosynthen ADC targeting a novel human epidermal growth factor receptor 2 that is in Phase 1 clinical trial.
Its preclinical products portfolio includes XMT-2068 and XMT-2175. It has strategic research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana Biosciences, LLC for the development of ADC product candidates.
The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005.
Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.
| Country | United States |
| Founded | 2001 |
| IPO Date | Jun 28, 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 102 |
| CEO | Martin Huber |
Contact Details
Address: 840 Memorial Drive Cambridge, Massachusetts 02139 United States | |
| Phone | (617) 498-0020 |
| Website | mersana.com |
Stock Details
| Ticker Symbol | MRSN |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001442836 |
| CUSIP Number | 59045L106 |
| ISIN Number | US59045L1061 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Martin H. Huber M.D. | President, Chief Executive Officer and Director |
| Brian C. DeSchuytner | Senior Vice President, Chief Financial Officer and Chief Operating Officer |
| Dr. Timothy B. Lowinger Ph.D. | Senior Vice President and Chief Science and Technology Officer |
| Alejandra Veronica Carvajal J.D. | Senior Vice President, Secretary and Chief Legal Officer |
| Mohan Bala Ph.D. | Senior Vice President and Chief Development Officer |
| Mikhail Papisov Ph.D. | Co-Founder |
| Ashish Mandelia | Vice President and Chief Accounting Officer |
| Jason Fredette | Senior Vice President of Investor Relations and Corporate Communications |
| Chuck Miller | Senior Vice President of Regulatory Affairs |
| Dr. Marc Damelin Ph.D. | Exe. Director and Head of Biology, Oncology, Antibody-Drug Conjugate ADC Discovery and Develop. |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 18, 2025 | PRE 14A | Other preliminary proxy statements |
| Apr 17, 2025 | SCHEDULE 13G/A | Filing |
| Mar 3, 2025 | 10-K | Annual Report |
| Mar 3, 2025 | 8-K | Current Report |
| Feb 28, 2025 | 8-K | Current Report |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Feb 5, 2025 | SCHEDULE 13G/A | Filing |
| Feb 5, 2025 | 8-K | Current Report |
| Jan 17, 2025 | 144 | Filing |
| Jan 17, 2025 | 144 | Filing |